Navigation Links
Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter

BRUSSELS, Belgium and GENEVA, Sept. 3 /PRNewswire/ -- Artelis SA and Selexis SA announced today a new milestone in CHO based monoclonal antibody production with the achievement of manufacturing yields of over 31 grams per liter. This record level was accomplished by applying two highly innovative technologies: (1) a high-performance stable Selexis CHO production cell line rapidly generated by industry leading scientists at Selexis SA using their proprietary Selexis Genetic Elements(TM) and (2) the application of iCELLis(TM) scalable, disposable, high-cell-density technology developed by the innovative scientists at Artelis.

The full program was concluded over about 4 months, starting with the development of a high-performance cell line development at Selexis, followed by cell transfer and manufacturing at Artelis. The culture media used throughout the study was industry standard cGMP grade and void of serum or any animal derived components.

Dr. Igor Fisch, Co-founder and CEO of Selexis commented on the achievements:

"The productivity and stability of the Selexis high-performance cell lines are a perfect fit for the iCELLis(TM) technology, which has the ability to reach incredibly high-cell-densities of up to 250 mio cells per ml". "The usefulness and potential applications of the combined approach could stretch across the biotech industry, beyond just large scale bioproduction".

Dr. Jose Castillo, Co-founder and President of Artelis commented on the achievements:

"These results show the power of the iCELLis(TM) technology. When combined with a high-performance cell line, like one from Selexis', we have the opportunity to reach ultra high productivity levels." "We firmly believe the iCELLis(TM) system will change the approach companies take for the small and large scale production of recombinant proteins."

Further details on this milestone achievement will be presented at the upcoming Bioprocess International Conference being held in Anaheim, California, September 23 -- 26, 2008.

Artelis and Selexis plan to expand the testing of the combined technologies by evaluating the iCELLis(TM) platform with Selexis generated HEK293 cells lines.

About the Artelis iCELLis(TM) Technology:

iCELLis (TM) is a proprietary, single-use, technology developed by Artelis. iCELLis(TM) is designed to achieve and maintain high-cell densities on macrocarriers in a fixed-bed system. Achieving high-cell densities allows compact iCELLis(TM) bioreactors to equal the productivity of much larger stirred-tank units. Depending on cell type and process, iCELLis(TM) can achieve 20-100x the volumetric productivity of a stirred-tank bioreactor.

iCELLis(TM) represents the next generation of disposable bioreactor technology, enabling process intensification in upstream processing by reducing bioreactor scale and simplifying operations.

About Artelis:

Artelis is an international and innovative SME founded in 2005. Capitalised by an American company listed on NASDAQ, Artelis is the privileged partner of world-leading pharmaceutical groups. The company has broad experience with disposable technologies: Artelis developed the Newmix(R) Jet Drive(TM), disposable mixing system, and co-developed the Nucleo(TM) disposable bioreactor together with ATMI Lifesciences and Pierre Guerin Biolafitte. Artelis is concerned by the process intensification needs in the biotech industry and dedicated to process development in disposable technologies. Artelis' mission is to create the future means of producing proteins, cells and viruses for key markets: monoclonal antibodies, cell therapy, vaccines and gene therapy. For more information, please visit

About the Selexis Genetic Elements(TM):

Selexis Genetic Elements (TM) are applied to control the dynamic organization of transgenes in the chromatin of eukaryotic production cells. The Selexis Genetic Elements(TM) enable the creation of loops of open chromatin upon the stable integration of the SGE containing vectors. Selexis Genetic Elements(TM) based vectors have been shown to significantly increase the population of independently transformed cells stably expressing the gene of interest at very high levels. Selexis Genetic Elements(TM) are available for out-license.

About Selexis SURE Cell Line Development(SM) Program: The Selexis SURE Cell Line Development(SM) program is a novel cell line development procedure designed to maximize the effectiveness of the Selexis technology. Using the Selexis SURE Cell Line Development program, Selexis scientists can generate high-performance stable minipools in as little as 5 week following transfection or high-performance clonal cell lines 12 weeks after transfection. Like the Selexis Genetic Elements(TM) the Selexis SURE Cell Line Development Program is available for out-license.

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services to speed the development of high performance mammalian cell lines. The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development(SM) process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.

For more information visit Selexis at

Selexis Genetic Elements(TM) and SURE Cell Line Development(SM) are trademarks of Selexis SA.

iCELLis(TM) is a trademark of Artelis SA.

SOURCE Selexis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
2. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
3. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
4. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
7. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
8. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
9. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
Post Your Comments:
(Date:10/9/2015)... DIEGO , Oct. 9, 2015 Ansun ... (Infectious Disease Society of America ) regarding the compassionate ... transplant patient on a respirator who was co-infected with ... a five-day course of therapy, O 2 requirement ... the patient was able to go off the respirator ...
(Date:10/8/2015)... October 9, 2015 ® ... diagnostic colonoscopy. The NOCT study also assessed the ... --> ® ) in adult patients ... study also assessed the compliance, safety, patient acceptability ... today announced positive top line results for its ...
(Date:10/8/2015)... PITTSBURGH , Oct. 8, 2015 /PRNewswire/ ... pharmaceutical company, will host a conference call and webcast ... ET to review the value to be created for ... TASE) through Mylan,s offer to acquire the company. During ... outlines the compelling proposition for Perrigo shareholders. Mylan,s offer ...
Breaking Medicine Technology:
... IDEV Technologies, Inc. (IDEV) today announced the firm ... Australia,s regulatory agency for medical drugs and devices, for ... and peripheral procedures. "We are pleased to ... SUPERA VERITAS in the Australian market later this year," ...
... 28, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the ... Paris, France. "The data we are ... an important new treatment option for patients with multiple ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... A new health tool that helps identify if a ... ( ) – just in time for the cold and flu season, which ... for many in the U.S., the real start of cold/flu season is the start ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington Beach ... system that uses clear, plastic aligners. This alternative to braces has become wildly ... allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, so ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... The Asthma ... the US Centers for Disease Control and Prevention (CDC) to improve the knowledge and ... that AAFA has been awarded a project by the CDC and allows AAFA to ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... individuals from all walks of life to save money on the high cost ... $25 per month per medication, individuals and families can receive their medications delivered ...
(Date:10/9/2015)... ... October 09, 2015 , ... Ryan Fox, ... largest recreational dispensaries in Colorado, says the latest figures on the state’s sales ... maturing into a legitimate industry. , Last month, according to the ...
Breaking Medicine News(10 mins):
... ... Integration project team including Drummond Group Inc., the trusted interoperability test lab, to conduct a ... project and leading the testing efforts with strong support from the project stakeholders. ... Austin, TX (PRWEB) December 7, ...
... ... medical research. , ... AZ (PRWEB) December 7, 2009 -- is doing its part to help find a ... Cure Catheters to its list of nearly 45,000 products., , ,Cure Medical is a forward-thinking ...
... , NEW ORLEANS, Dec. 7 ... Ruth Pettengell, M.D. of St. George,s Hospital, University of London during ... Meeting updated results from the pivotal phase III EXTEND (PIX 301) ... or refractory, aggressive non-Hodgkin,s lymphoma ("NHL") patients who have failed ...
... , OAK BROOK, Ill., Dec. ... academic medical center (AMC) members for their achievements in ... 10 organizations are noted for modeling best practices in ... ) , The winners were determined using 2008 ...
... the loss of a key segment of DNA can lead to ... this kind of genetic alteration can cause obesity. The results are ... Dr Sadaf Farooqi from the University of Cambridge and Dr Matt ... with severe obesity. The team scanned each child,s entire genome ...
... Dec. 6 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... 003-A1 study, known as the 003 trial, demonstrating that carfilzomib ... patients. These data were presented today at the ASH/ASCO Joint ... of Hematology (ASH) in New Orleans. Enrollment in this trial ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: